This clinical trial is focused on studying treatments for patients with advanced ovarian cancer, which can also include primary peritoneal cancer and fallopian-tube cancer. The study involves two main treatments. The first treatment is a combination of chemotherapy drugs called paclitaxel and carboplatin, followed by a maintenance treatment with a medication called niraparib. The second treatment adds another medication called bevacizumab to the initial chemotherapy, followed by maintenance with both niraparib and bevacizumab. The purpose of the study is to determine which treatment approach is more effective in improving the time patients live without the cancer getting worse over a period of 24 months.
Participants in the study will receive one of the two treatment plans after undergoing a complete surgery to remove visible cancer. The study will begin with the chemotherapy phase, where patients will receive paclitaxel and carboplatin. In one group, patients will also receive bevacizumab during this phase. After the chemotherapy phase, patients will continue with a maintenance phase where they will receive niraparib, and in the second group, they will also continue with bevacizumab. The study will monitor patients over time to see how long they remain free from cancer progression and to assess the overall safety of the treatments.
The study aims to provide valuable information on whether adding bevacizumab to the treatment plan can improve outcomes for patients with advanced ovarian cancer. The trial will also look at other important factors such as the time until patients need further treatment and overall survival rates over five years. This research is important for understanding the best ways to treat these types of cancer and to improve the quality of life for patients.
Belgium 
France 
Italy 
Spain 
